FibroDynamx is a drug target discovery spin out from the University of Calgary, focusing on regenerative medicines. We have a unique platform for drug target identification based on regenerative healing models (reindeer). Our first asset is a protein-based drug that improves scarring and skin regeneration by 10-fold in pre-clinical models. There are no existing treatments on the market that prevent scarring, however medical need and pharmaceutical demand is considerable, in fact the global market for scar treatment is projected to reach $32B USD by 2035.